Latest CancerVax Stories
Prior knowledge of phase III clinical trials of new drugs and Food and Drug Administration (FDA) regulatory decisions may affect the price of a drug company's stock according to a study published September 26 in the Journal of the National Cancer Institute.
SAN DIEGO, June 22, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), a therapeutic oncology company developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that Anthony E Maida, III, Ph.D., has been appointed to OncoSec's board of directors and will chair its audit committee. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) For over 20 years, Dr.
BETHESDA, Md., June 8, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has made changes and substantially expanded its management team, adding several highly experienced executives. Ms.
A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2.
SAN DIEGO, April 11, 2011 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).
There could soon new treatment for one of the most deadly forms of cancer, thanks to a study from the University of East Anglia and Children's Hospital Boston.
- Withering but not falling off, as a blossom that persists on a twig after flowering.